Short Interest in Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Decreases By 7.0%

Fulcrum Therapeutics, Inc. (NASDAQ:FULC) was the recipient of a large drop in short interest during the month of December. As of December 15th, there was short interest totalling 4,260,000 shares, a drop of 7.0% from the November 30th total of 4,580,000 shares. Based on an average daily trading volume, of 1,040,000 shares, the short-interest ratio is currently 4.1 days.

Fulcrum Therapeutics Trading Up 0.4 %

NASDAQ:FULC traded up $0.02 during midday trading on Wednesday, hitting $4.70. 555,369 shares of the stock were exchanged, compared to its average volume of 1,003,506. The business has a 50-day moving average price of $3.78 and a two-hundred day moving average price of $5.61. The company has a market capitalization of $253.51 million, a price-to-earnings ratio of -15.16 and a beta of 2.14. Fulcrum Therapeutics has a one year low of $2.86 and a one year high of $13.70.

Institutional Trading of Fulcrum Therapeutics

Institutional investors have recently modified their holdings of the company. National Bank of Canada FI increased its holdings in shares of Fulcrum Therapeutics by 869.6% in the second quarter. National Bank of Canada FI now owns 4,460 shares of the company’s stock valued at $28,000 after buying an additional 4,000 shares in the last quarter. Profund Advisors LLC acquired a new stake in shares of Fulcrum Therapeutics during the second quarter worth $68,000. China Universal Asset Management Co. Ltd. lifted its holdings in shares of Fulcrum Therapeutics by 64.4% during the third quarter. China Universal Asset Management Co. Ltd. now owns 12,002 shares of the company’s stock valued at $43,000 after purchasing an additional 4,701 shares during the last quarter. Renaissance Technologies LLC acquired a new position in shares of Fulcrum Therapeutics in the 2nd quarter valued at $82,000. Finally, Walleye Capital LLC purchased a new position in Fulcrum Therapeutics in the 3rd quarter worth about $59,000. Institutional investors and hedge funds own 89.83% of the company’s stock.

Wall Street Analysts Forecast Growth

FULC has been the topic of several analyst reports. Cantor Fitzgerald downgraded shares of Fulcrum Therapeutics from an “overweight” rating to a “neutral” rating in a report on Thursday, September 12th. Royal Bank of Canada reiterated a “sector perform” rating and issued a $4.00 price target on shares of Fulcrum Therapeutics in a research report on Thursday, November 14th. Leerink Partners reissued a “market perform” rating and issued a $4.00 target price on shares of Fulcrum Therapeutics in a research note on Thursday, September 12th. Stifel Nicolaus lowered Fulcrum Therapeutics from a “buy” rating to a “hold” rating and dropped their target price for the company from $22.00 to $3.00 in a research note on Thursday, September 12th. Finally, Bank of America lowered shares of Fulcrum Therapeutics from a “neutral” rating to an “underperform” rating and decreased their price target for the company from $10.00 to $2.00 in a report on Thursday, September 12th. One analyst has rated the stock with a sell rating, six have issued a hold rating and three have given a buy rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus price target of $9.33.

Fulcrum Therapeutics Company Profile

Fulcrum Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy is under phase III clinical trial; and pociredir, a fetal hemoglobin inducer for the treatment of sickle cell disease and beta-thalassemia is under phase I clinical trial.